Put Options

9 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$143.93 - $224.51 $1.37 Million - $2.13 Million
9,500 New
9,500 $2.13 Million
Q1 2022

May 17, 2022

BUY
$146.52 - $269.56 $732,600 - $1.35 Million
5,000 Added 161.29%
8,100 $1.53 Million
Q4 2021

Feb 15, 2022

SELL
$248.56 - $389.34 $1.54 Million - $2.41 Million
-6,200 Reduced 66.67%
3,100 $840,000
Q3 2021

Nov 16, 2021

SELL
$249.6 - $403.14 $798,720 - $1.29 Million
-3,200 Reduced 25.6%
9,300 $3.38 Million
Q1 2021

May 18, 2021

SELL
$260.64 - $382.12 $834,048 - $1.22 Million
-3,200 Reduced 20.38%
12,500 $4.35 Million
Q4 2020

Feb 17, 2021

BUY
$221.31 - $316.61 $3.08 Million - $4.4 Million
13,900 Added 772.22%
15,700 $4.06 Million
Q3 2020

Nov 17, 2020

BUY
$189.18 - $286.44 $340,524 - $515,592
1,800 New
1,800 $516,000
Q1 2020

May 15, 2020

SELL
$121.84 - $173.19 $925,984 - $1.32 Million
-7,600 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$115.78 - $208.34 $879,928 - $1.58 Million
7,600 New
7,600 $1.26 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.2B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.